ALTEOGEN Inc. 196170

RAHWAY, N.J., September 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administer

Novartis (SWX:NOVN) is back in focus after reporting positive Phase III REMODEL-1 and REMODEL-2 results for its oral BTK inhibitor remibrutinib in relapsing multiple sclerosis, supporting planned global regulatory filings. At a share price of CHF131.32, Novartis has seen building momentum, with a 7 day share price return of 5.36% and a 90 day share price return of 11.31%. Total shareholder return sits at 30.21% over one year and 108.91% over five years, helped recently by the remibrutinib...

The agreement includes option exercise fees, milestone payments, and royalties on net sales of products commercialised with ALT-B4 technology.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

Alteogen's platform can turn intravenous biologics into injections, but payments depend on multiple products reaching milestones.

Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it has entered into an option and license agreement with Novartis for the development and commercialization of subcutaneous (SC) products utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology.

Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.

Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it has entered into an exclusive license agreement with a global pharmaceutical company for the development and commercialization of a subcutaneous (SC) biologic product utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology.

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

As global markets navigate a complex landscape marked by rising inflation concerns and geopolitical tensions, small-cap stocks have shown resilience, outperforming their larger counterparts amid renewed enthusiasm for artificial intelligence. In this environment, identifying high growth tech stocks involves looking for companies that can leverage technological advancements and maintain robust earnings potential despite economic uncertainties.

As global markets navigate a complex landscape marked by geopolitical tensions and economic shifts, the Asian tech sector continues to capture attention with its potential for high growth, especially as AI-related investments gain momentum. In this environment, identifying promising tech stocks involves assessing companies' ability to innovate and adapt to changing consumer demands while effectively managing costs amidst rising inflationary pressures.

Amidst a backdrop of heightened geopolitical tensions, persistent inflation concerns, and volatile oil prices, global markets have experienced significant fluctuations with U.S. equity indexes finishing lower for the week. As central banks across major economies signal caution and maintain interest rates amid these uncertainties, investors are increasingly focused on identifying high growth opportunities in sectors like technology that can navigate such challenging environments effectively.

Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology.

As global markets grapple with concerns over AI disruption and mixed economic indicators, Asian tech stocks are drawing attention for their potential resilience and growth prospects. In this dynamic environment, a good stock to watch in the high-growth tech sector is one that demonstrates strong innovation capabilities and adaptability to evolving market trends.

As Asian markets navigate a landscape marked by regulatory changes and geopolitical tensions, investors are increasingly focused on sectors like artificial intelligence and technology that show resilience amid global shifts. In this context, companies with strong insider ownership can be particularly appealing, as they often indicate confidence from those closest to the business's operations and strategy.

As global markets kicked off the year with a rally, small-cap and value shares have notably outpaced large-cap growth stocks, driven by investor optimism despite signs of weakness in the U.S. labor market and ongoing geopolitical tensions. In this environment, high-growth tech stocks like ALTEOGEN are drawing attention for their potential to thrive amidst economic shifts, as investors look for companies that can leverage innovation and adaptability to navigate changing market dynamics.